Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS: DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged ≥18 years) with type 2 diabetes and inadequate glycemic control (HbA1c 8.0–12.0% [64–108 mmol/mol]) despite stable metformin monotherapy (≥1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS: At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA1c was greater with exenatide QW plus dapagliflozin (−1.70% [0.11]) versus exenatide QW plus placebo (−1.29% [0.12]; P = 0.007) and dapagliflozin plus placebo (−1.06% [0.12]; P < 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS: In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
In the citing paper
“In a randomized, controlled trial of patients with type 2 diabetes and inadequate glycemic control while on stable metformin monotherapy, compared to dapagliflozin alone, exenatide plus dapagliflozin produced clinically relevant changes in body weight, fasting plasma glucose, 2-h post-prandial glucose, and systolic blood pressure [115].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Self-citationZinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266
Self-citationDel Prato, S., Nauck, M., Durán‐Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., & Parikh, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 233
Jabbour, S., Seufert, J., Scheen, A., Bailey, C. J., Karup, C., & Langkilde, A. M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 157
Self-citationJabbour, S. A., Frías, J. P., Hardy, E., Ahmed, A., Wang, H., Öhman, P., & Guja, C. (2018) · Diabetes Care · doi:10.2337/dc18-0680 · Cited by 97
Self-citationLundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72
Self-citationBusch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 63
Genovese, S., Mannucci, E., & Ceriello, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0499-6 · Cited by 33
Harashima, S., Inagaki, N., Kondo, K., Maruyama, N., Otsuka, M., Kawaguchi, Y., & Watanabe, Y. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13267 · Cited by 27
Philis‐Tsimikas, A., Wysham, C., Hardy, E., Han, J., & Iqbal, N. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.012 · Cited by 26
Self-citationDurability of response to dapagliflozin: a review of long-term efficacy and safety
Jabbour, S. A. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1354822 · Cited by 17
Self-citationSGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
Block, C. E. M. D. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30031-7 · Cited by 14
Cited by
Gourdy, P., Darmon, P., Diévart, F., Halimi, J., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 157
“The only exception was DURATION-8, a 104-week, active-controlled, phase III trial, evaluating the combination of once-weekly subcutaneous exenatide plus once-daily oral dapagliflozin, simultaneously added to stable metformin monotherapy, in 695 patients with T2DM and poor glycemic control [36].”
BackgroundCombination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
“Early studies such as DURA-TION-8 in patients with T2DM, showed that combination treatment with SGLT2 inhibitors and GLP1 receptor agonists had greater beneficial effects on blood glucose levels, body weight and blood pressure in people with diabetes than either therapy alone 105 .”
Li, C., Jie, L., Jiang, M., & Wang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838277 · Cited by 114
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Patel, R. P., Wadid, M., Makwana, B., Kumar, A., Khadke, S., Bhatti, A. W., Banker, A., Husami, Z., Labib, S. B., Venesy, D. M., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.07.006 · Cited by 94
Metadata
- Authors
- Jabbour, S. A., Frías, J. P., Ahmed, A., Hardy, E., Choi, J., Sjöström, C. D., & Guja, C.
- Affiliations
- Thomas Jefferson University (US)
- National Research Institute (US)
- Apex Medical Research, Chicago, IL
- AstraZeneca (United States) (US)
- Statum Research, Irvine, CA
- AstraZeneca (Sweden) (SE)
- Carol Davila University of Medicine and Pharmacy (RO)
- Corresponding author
- Jabbour, Serge A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-08-18
- Volume
- 43
- Issue
- 10
- Pages
- 2528-2536
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7510043
- OpenAlex
- W3065084537
- Cited by
- 69
- References
- 17
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 8
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, dapagliflozin, type 2 diabetes, glycemic control, HbA1c, long-term efficacy, long-term safety, weight loss, systolic blood pressure, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, combination therapy, postprandial blood glucose, fasting blood glucose
- MeSH terms
- Exenatide, Adolescent, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.